Table 3 Clinical manifestations of Henoch–Schönlein purpura patients with increased fecal calprotectin levels
Variable | Total HSP patients (n = 69) | Fecal calprotectin > 50 mg/kg (n = 45) | Fecal calprotectin < 50 mg/kg (n = 24) | P value |
|---|---|---|---|---|
Duration of admission (days) | 5.41 ± 5.27 | 6.33 ± 5.88 | 3.61 ± 3.22 | 0.043* |
Patients with gastrointestinal symptoms | 40 (58.0%) | 35 (77.8%) | 5 (20.8%) | 0.000* |
Upper gastrointestinal tract involvement | 22/40 (55.0%) | 19/35 (54.3%) | 3/5 (60.0%) | 1.000 |
Lower gastrointestinal tract involvement | 18/40 (45.0%) | 16/35 (45.7%) | 2/5 (40.0%) | |
Duration of gastrointestinal symptoms (days) | 2.88 ± 4.02 | 3.89 ± 4.35 | 1.00 ± 2.41 | 0.001* |
HSP clinical score | 1.99 ± 1.53 | 2.36 ± 1.61 | 1.29 ± 1.08 | 0.005* |
Gastrointestinal involvement score | 0.93 ± 0.93 | 1.27 ± 0.89 | 0.29 ± 0.62 | 0.000* |
HSP recurrence | 23 (33.3%) | 18 (40.0%) | 5 (20.8%) | 0.108 |
Gastrointestinal symptom recurrence | 19 (27.5%) | 15 (33.3%) | 4 (16.7%) | 0.167 |
Positive stool occult blood result | 17 (24.6%) | 16 (35.6%) | 1 (4.2%) | 0.003* |